BERLIN (AP) — German vaccine-maker IDT Biologika said Friday it plans to bottle this year some 10 million doses of the coronavirus shot developed by AstraZeneca.
IDT Biologika and AstraZeneca previously announced they would expand production capacity for the British-Swedish company's vaccine at a plant in the German town of Dessau by the end of 2022.
The new agreement was made possible because a third manufacturer, Merz Pharma, relinquished the production capacity it had reserved with IDT for the second quarter.
IDT produces vaccines for several pharmaceutical companies. In March, the company announced that for three months it would make the single-dose COVID-19 shot developed by Johnson & Johnson.
Chief Executive Officer Juergen Betzing said Friday that IDT was also in talks with the developers of Russia's Sputnik V shot, which has yet to be approved for use in the European Union.
The AstraZeneca vaccine is restricted to people over 60 in Germany due to concerns over rare blood clots in some recipients. Among those who received it recently are German Chancellor Angela Merkel and President Frank-Walter Steinmeier.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
